|

Novel Approaches to Target MECOM/EVI1 in AML

RECRUITINGN/ASponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto
Actively Recruiting
PhaseN/A
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
Started2023-12-13
Est. completion2026-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05839392

Summary

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* AML with MECOM or atypical 3q26 rearrangements.
* Age ≥18.
* Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion Criteria:

* None

Conditions2

AML, AdultCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.